Village Farms International, Inc. (VFF) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance, including a significant increase in global cannabis sales, net income, and adjusted EBITDA. The share repurchase program indicates confidence in the company's valuation. While there were concerns about the German market, management expects growth to rebound. The strategic expansion and operational efficiencies in Canada and internationally are promising. The lack of specific guidance on cost initiatives is a minor concern, but overall, the positive financial metrics and strategic plans suggest a positive stock price movement.
Key Financial Performance
Global cannabis sales Grew by 17% year-over-year, driven by partial contributions from the expanding Netherlands business and a sixfold increase in international export sales. This growth reflects the company's leadership position as a major EU-GMP certified cannabis operator.
Net income from continuing operations $21 million or $0.19 per share, a $49 million improvement compared to the prior year. This improvement is attributed to strong execution of the long-term plan and strategic focus on margin performance, profitability, and cash generation.
Adjusted EBITDA from continuing operations $50 million, an improvement of $48 million year-over-year. This reflects the company's focus on improving operational efficiency and profitability.
Cash flow from continuing operations $58 million, an improvement of $44 million compared to 2024. This increase is due to enhanced profitability and operational efficiency.
Net sales in Q4 Increased by 9% year-over-year to just shy of $50 million. This growth was driven by a 10% increase in Canadian cannabis sales and a nearly 400% increase in international export sales.
Canadian cannabis gross margin 43% in Q4, up from 3% in the same quarter last year. This improvement is due to a higher proportion of higher-margin international export sales and a focus on high-margin SKUs in the retail branded channel.
Canadian cannabis adjusted EBITDA $14.3 million in Q4, up from negative $9.1 million in the same quarter last year. This improvement reflects better gross margins and operational efficiencies.
Canadian cannabis cash flow from operations $21.5 million in Q4, an increase of $24.8 million year-over-year. This growth is attributed to improved profitability and operational performance.
Netherlands cannabis sales $3.3 million in Q4, with adjusted EBITDA of $700,000. The profitability was impacted by increased operating expenses due to staffing for the Phase 2 facility launch.
U.S. cannabis gross margin 60% in Q4, slightly down year-over-year, reflecting challenges from state actions and unregulated hemp products.
Consolidated adjusted EBITDA margin 17.3% in Q4, compared to negative 6.4% in the same quarter last year. This improvement is due to better operational performance and profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EU-GMP certified cannabis products: Expanded international export sales by over sixfold, leveraging EU-GMP certification to meet stringent international regulations.
Netherlands cannabis operations: Launched pilot program in April 2025, achieving positive net income within three quarters of revenue performance.
New product innovations in the Netherlands: Introduced 10 new product offerings across multiple formats, targeting premium product categories.
Global cannabis sales: Increased by 17% year-over-year, driven by international expansion and Netherlands operations.
Canadian cannabis market: Maintained top 5 market share and #1 position in dried flower; retail branded sales remained flat but with improved gross margins.
International market expansion: Expanded exports to Germany and other jurisdictions, with plans to ship to multiple new markets in 2026.
Capacity expansion in Canada: Delta 2 facility expansion on track, expected to add 40 metric tons of annual production by mid-2027.
Capacity expansion in the Netherlands: Phase 2 facility nearing completion, expected to increase annual production capacity to 10 metric tons.
Operational efficiencies: Improved gross margins in Canadian cannabis to 43%, above the target range, and reduced SG&A expenses as a percentage of sales.
Privatization of legacy produce business: Transitioned to focus on cannabis operations, retaining optionality for advanced greenhouse assets in Canada and Texas.
Share repurchase program: Repurchased 813,000 shares in Q4 2025 and 1.1 million shares in Q1 2026, reflecting a balanced capital allocation strategy.
Incremental growth investments: Secured $15 million delayed draw term loan to enhance EU-GMP capabilities and fund capacity expansions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Labor Strike in British Columbia: The flow of cannabis in the province of British Columbia was impacted by a labor strike in Q4, which reduced Q4 sales by approximately $2.5 million.
Supply Constraints: Near-term supply constraints are temporarily holding back the company from meeting customer demand, particularly in Canada and international markets.
Seasonality in Canadian Cannabis Business: The Canadian cannabis business experiences seasonality due to variances in growing climate, leading to sequential declines in production and revenue during the fourth quarter.
Delayed International Orders: Some international orders from Germany expected to ship in late Q4 were delayed to Q1, impacting quarterly performance.
Biomass Constraints: The company is facing biomass constraints, which are limiting its ability to meet increasing demand.
Increased Operating Expenses in Netherlands: Profitability in the Netherlands was impacted by increased operating expenses due to ramping up staffing for the launch of the Phase 2 facility.
Canadian Income Tax Payments: The company accrued Canadian income taxes of $16 million in 2025, which were paid in February 2026, impacting cash flow.
Soft Pricing in Produce Operations: The continuing produce operations experienced softer year-on-year pricing, leading to a 21% decline in sales.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to return to sequential growth in international exports in Q1 2026 and anticipates shipping to multiple new jurisdictions over the next several months.
Capacity Expansion: The Delta 2 facility expansion in Canada is on track and expected to contribute an additional 15 metric tons of production in late Q2 2026, with full capacity by mid-2027, adding 40 metric tons annually. In the Netherlands, the Phase 2 Groningen facility is nearing completion, with planting expected by the end of March 2026 and full capacity by Q2 2026, increasing annual production capacity to approximately 10 metric tons.
Profitability and Cash Flow: The company aims to continue driving profitable growth in 2026 and beyond, supported by strong demand domestically in Canada and internationally. The company also plans to maintain a balanced approach to capital allocation, including share repurchases and investments in growth.
Market Position: The company plans to leverage its leadership position in the Canadian cannabis market and its EU-GMP certification to expand its market share in premium product categories in the Netherlands and other international markets.
Capital Investments: The company has allocated $3 million to expand EU-GMP capabilities in 2026 and has secured an incremental $15 million delayed draw term loan to fund additional operational enhancements.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program or plans to distribute dividends to shareholders was made in the transcript.
Share Repurchase Program: The company has an active share repurchase program approved by the Board at the end of September. The program allows for the purchase of up to just under 5 million common shares, representing 5% of the issued and outstanding shares. During Q4, the company repurchased approximately 813,000 shares at a cost of $3 million. The program continued into Q1 2026, with an additional 1.1 million shares repurchased at a cost of $3.7 million. The management and Board view this as a balanced approach to capital allocation aimed at driving shareholder returns.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What does the share repurchase program indicate about the company's valuation and business trajectory?
A:The company is confident in its cash generation and believes the $10 million share repurchase program will not impact business operations or growth opportunities. They are taking a balanced approach and will reevaluate the program as they move forward.
Q:Should investors be concerned about growth in the German market given the sequential decline in import volumes in Q4?
A:The decline in German imports (4%) and Canadian imports (11%) was due to regulatory uncertainty, which has since abated. The company expects growth to return in Q1 and noted that delayed orders from Q4 to Q1 would have improved their Q4 performance. They see increasing demand as Germany applies stricter quality and market route restrictions.
Q:How does the company plan to utilize the additional capacity from Delta 2 for international versus Canadian markets?
A:Canada remains the primary market, and the company is balancing demand between Canada and international markets. They are investing in additional capacity and have the ability to more than double their 2027 forecast with current assets. Both markets are treated as equal priorities.
Q:What initiatives are in place to lower cultivation costs, and what savings are expected from the Delta 2 facility?
A:The company continues to improve and reduce costs annually, exceeding their cost improvement targets. They did not disclose specific cost-per-gram figures but highlighted ongoing cost reductions and efficiencies, including leveraging the Delta 2 facility.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on cost-per-gram figures despite being asked about cultivation cost initiatives. Their response lacked numerical data and relied on general statements about cost improvements.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Canada Texas
Congratulations member
Director
Drachten capacity
EU GMP
Farms stewardship
Netherlands expansion
Netherlands license
Netherlands year
Phase facility
Village Farms
approach world
asset Canada
cannabis operator
capability
capital behalf
contribution Netherlands
crawl approach
development
evidence
impairment
income cash
income tax
inventory
launch
legacy produce
portfolio
produce year
program
record
remainder
reminder
respect
stewardship capital
supply constraint
ton
year work
VFF Transcript
Village Farms International, Inc. (VFF) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call highlights strong financial performance, including a significant increase in global cannabis sales, net income, and adjusted EBITDA. The share repurchase program indicates confidence in the company's valuation. While there were concerns about the German market, management expects growth to rebound. The strategic expansion and operational efficiencies in Canada and internationally are promising. The lack of specific guidance on cost initiatives is a minor concern, but overall, the positive financial metrics and strategic plans suggest a positive stock price movement.
Village Farms International, Inc. (VFF) Q3 2025 Earnings Call Transcript
Positive11-10
The earnings call highlights strong financial performance, with record net sales, net income, and EBITDA. Growth in Canadian and Netherlands cannabis markets is robust, with significant international expansion plans. Despite some uncertainties in the Q&A, the optimistic guidance, especially in international markets, aligns with a positive outlook. The company's strong financial metrics, optimistic guidance, and strategic market expansion drive a strong positive sentiment, likely resulting in a stock price increase over the next two weeks.
Village Farms International, Inc. (VFF) Q2 2025 Earnings Call Transcript
Positive8-11
The earnings call highlights strong international growth, improved margins, and a solid net cash position. Despite a decline in Canadian retail sales, the focus on high-margin products and international expansion is promising. The Q&A reveals management's strategic focus on growth and profitability, with potential upside from U.S. regulatory changes. Positive factors outweigh concerns, suggesting a positive stock price movement.
Village Farms International, Inc. (VFF) Q1 2025 Earnings Call Transcript
Unknown5-13
The earnings call presents a mixed picture: international expansion and improved margins are positive, but declining revenues and increasing losses are concerning. The Q&A session highlights stable pricing and potential growth in the Netherlands, but management's vague responses on valuation and M&A opportunities raise uncertainties. The company's transition and cash proceeds from the joint venture could enhance future returns, but operational risks remain. Given the small market cap, the stock may react more strongly, but overall, the sentiment is balanced, leading to a neutral prediction.
VFF Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
